Journal of Hepatology and Gastrointestinal disorders
Open Access

Microbiological Evaluation and Role of Mucorales Fungi of Gastrointestinal Mucormycosis

Yan Bakman^{* *}Correspondence: Yan Bakman, Department of Gastroenterology, University of Minnesota, Minneapolis, USA, Email:

Author info »

About the Study

Gastrointestinal mucormycosis is a rare but serious form of fungal infection caused by fungi belonging to the order. These fungi are ubiquitous in the environment and typically affect individuals with weakened immune systems or underlying conditions that predispose them to fungal infections. Gastrointestinal mucormycosis can manifest in various parts of the gastrointestinal tract, including the stomach, intestines, and rarely, the liver and spleen. The infection is aggressive and can lead to significant morbidity and mortality if not promptly diagnosed and treated.

Microbiological evaluation

Gastrointestinal mucormycosis typically affects immunocompromised individuals, including those with poorly controlled diabetes, organ transplant recipients, and patients receiving immunosuppressive therapy. The infection arises from fungi of the Mucorales order, primarily Rhizopus species, which invade the gastrointestinal tract through ingestion of fungal spores or extension from nearby infected tissues.

Microbiological evaluation of gastrointestinal mucormycosis involves several key aspects. Diagnosis is challenging and often requires a high index of suspicion, as clinical symptoms can mimic other gastrointestinal conditions. Histopathological examination of tissue biopsies reveals non-septate hyphae with right-angle branching, characteristic of Mucorales. Culturing of specimens on appropriate media can further identify the specific fungal species and guide antifungal susceptibility testing.

In addition to traditional microbiological methods, molecular techniques such as PCR assays targeting fungal DNA are increasingly utilized for rapid and specific detection. These methods enhance diagnostic accuracy and allow early initiation of targeted antifungal therapy, typically involving liposomal amphotericin B as first-line treatment.

Overall, a multidisciplinary approach involving microbiologists, pathologists, and infectious disease specialists is important for the timely and accurate microbiological evaluation of gastrointestinal mucormycosis. This collaborative effort facilitates prompt diagnosis and management, improving patient outcomes in this potentially life-threatening infection.

Mucorales fungi

Mucorales fungi, particularly those of the genus Rhizopus, play a central role in gastrointestinal mucormycosis. These fungi belong to the order Mucorales and are ubiquitous in the environment, commonly found in soil, decaying organic matter, and food. They can cause invasive infections in immunocompromised individuals, including those with poorly controlled diabetes, hematologic malignancies, solid organ transplants, or receiving immunosuppressive therapies.

Pathogenesis: Mucorales infect the gastrointestinal tract through ingestion of fungal spores or direct extension from adjacent infected tissues. The fungi invade blood vessels, causing tissue necrosis and thrombosis, which leads to ischemia and infarction. This aggressive angioinvasive nature is characteristic of mucormycosis and contributes to its high morbidity and mortality.

Clinical manifestations: Gastrointestinal mucormycosis presents with a range of symptoms depending on the site and extent of infection. Abdominal pain, nausea, vomiting, and gastrointestinal bleeding are typical symptoms. Severe cases may progress to bowel necrosis, perforation, or obstruction, necessitating urgent surgical intervention.

Diagnostic features: Histopathological examination of tissue biopsies is essential for diagnosing gastrointestinal mucormycosis. Biopsies typically reveal non-septate hyphae with right-angle branching, characteristic of Mucorales fungi. Microbiological cultures further identify the specific species involved, aiding in targeted antifungal therapy.

Treatment: Early initiation of treatment is essential and typically involves systemic antifungal therapy, with liposomal amphotericin B as the preferred first-line agent due to its activity against Mucorales fungi. Surgical intervention may be necessary to remove necrotic tissue and improve drug penetration in localized disease or severe cases.

Prognosis: Despite aggressive management, gastrointestinal mucormycosis carries a high mortality rate, primarily due to delayed diagnosis, underlying immunocompromised state of the patient, and rapid disease progression.